Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPEPPS | P55786 | 12/20 | 1.00 |
| ▸ | ANPEP | P15144 | 10/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.99 |
| ▸ | NPC1 | O15118 | 1/20 | 0.99 |
| ▸ | RAB9A | P51151 | 1/20 | 0.99 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.99 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Puromycin SCHEMBL14583797 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL20393806 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL14583945 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL22409382 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL3042415 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL21306559 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL24206459 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL20815730 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL22348910 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL21481061 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 140664 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146259-A1 | COMPOSITIONS AND SYSTMES FOR HERPES SIMPLEX VIRUS PACKAGING AND USES THEREOF | Opentrons LabWorks Inc. (US) | 2026-05-28 | — | — | US | claimed |
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4746924-A1 | NON-NATURAL BUILDING BLOCKS FOR ENHANCED TRANSLATION AND STABILITY OF MRNA | Eleven Therapeutics Ltd (IL) | 2026-05-27 | — | — | EP | claimed |
| CN-122080230-A | Nano decoy receptor for blocking IL-17 signal path and preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122081237-A | Engineered enucleated mesenchymal stem cells, and preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122081332-A | ShRNA for silencing KAT8 and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122081407-A | Integrin alpha 6 stable low-expression lung cancer cell strain and construction method thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122081224-A | Method for constructing humanized brain organoid model of early-onset Alzheimer disease and application of humanized brain organoid model | — | 2026-05-26 | — | — | CN | claimed |
| CN-122081406-A | Virus vector for inhibiting angiogenesis by targeting KIF4A as well as preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026103922-A1 | CHIMERIC SHUTTLING RECEPTOR | 深圳市湾岛细胞科技有限公司 | 2026-05-21 | — | — | WO | claimed |
| EP-0409406-A2 | Aryl-substituted amine derivatives useful in cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-01-23 | — | — | EP | claimed |
| WO-1990015599-A1 | MEDICAMENTS USEFUL IN CANCER THERAPY AND HAVING ANTIHISTAMINIC PROPERTIES | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-12-27 | — | — | WO | claimed |
| WO-1990008584-A1 | NOVEL AMINOGLYCOSIDE AFFINITY MEDIA FOR SEPARATION OF MACROMOLECULES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE (US) | 1990-08-09 | — | — | WO | claimed |
| EP-0332104-A2 | Chemically regulatable DNA sequences and genes and uses thereof | CIBA-GEIGY AG (CH) | 1989-09-13 | — | — | EP | claimed |
| US-4753984-A | Water soluble macromolecular prodrugs, their preparation and their use as antitumor and antiparasite medicines | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1988-06-28 | — | — | US | claimed |
| EP-0245063-A1 | Eukaryotic resistance markers | Antibioticos S.A. (ES) | 1987-11-11 | — | — | EP | claimed |
| WO-1987006612-A1 | EUKARYOTIC RESISTANCE MARKERS | ABLEWHITE, ALAN, JAMES (GB) | 1987-11-05 | — | — | WO | claimed |
| US-4617293-A | Flavonoid phosphate salts of aminoglycoside antibiotics | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1986-10-14 | — | — | US | claimed |
| EP-0174810-A2 | Multidrug resistance in mammalian cell lines and isolation of determinant glycoprotein DNA | HSC Research Development Corporation (CA) | 1986-03-19 | — | — | EP | claimed |
| US-4148887-A | SUGAR ESTER WITH A METHYL SULFOXIDE | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-10 | — | — | US | claimed |